改变血友病管理:基因治疗临床试验的教训
Md Sadique Hussain1,2, Mudasir Maqbool3, Mohammed M Arab4
1Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, 248007, India. sadiquehussain007@gmail.com.
Molecular biotechnology
|June 30, 2025
概括
基因疗法为血友病护理提供了一种革命性的方法,使持续的因子生产成为可能,并减少对因子输液的需求. 目前正在进行的研究旨在克服诸如免疫反应等挑战,以便广泛采用.
科学领域:
- * 血液学和遗传医学
- * 生物技术和病毒载体开发
背景情况:
- *基因疗法在血友病管理中呈现了一种范式转变,朝着内源性凝血因子合成迈进.
- * 早期使用腺相关病毒 (AAV) 载体治疗B型血友病的基因治疗试验面临免疫反应和短暂表达等局限性.
- *血友病A基因治疗的发展受到第八因子 (FVIII) 基因的大小的阻碍.
研究的目的:
- *审查血友病基因疗法的进展,重点关注载体改善和临床结果.
- * 突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出突出
- *讨论新型治疗策略的潜力,以提高基因疗法的疗效.
主要方法:
- *对血友病B的腺相关病毒 (AAV) 载体进行临床前和临床研究的综述,包括自我补充的AAV和子优化的迷你因子IX (FIX) 构造.
- *使用B域删除的FVIII构造对血友病A的AAV血型5 (AAV5) 载体应用的分析.
- *对血友病基因治疗的长期有效性和安全性进行第三阶段研究数据的评估.
主要成果:
- *在B型血友病患者中,因子IX (FIX) 活性显著改善,持续表达超过8年,导致出血减少和预防性治疗.
- *持续的FVIII表达和大量减少在血友病A患者使用AAV5载体的出血,有些人达到接近正常的凝血.
- *第三期试验证实了长期的疗效和安全性,最常见的不良事件是短暂的转氨酶升高.
结论:
- *基因疗法,特别是改进的AAV载体技术,在治疗血友病A和B方面显示出显著的潜力.
- * 持续存在的挑战包括免疫性,肝毒性和可变的表达水平,需要进一步研究.
- *新兴的策略,如晶状病毒载体和基因编辑,有望优化血友病基因治疗结果.
更多相关视频
相关概念视频
00:59Gene Therapy
25.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.9K
01:29Microorganisms in Medicine and Therapeutics
360
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
360
01:29Venous Thrombosis III: Interprofessional Care
27
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
27
00:49What is Genetic Engineering?
75.6K
Overview
75.6K
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
921
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
921